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Abstract 
According to current ESMO – MASCC guidelines, a combination of a neurokinin-1 receptor 
antagonist (NK1RA), dexamethasone and a 5-HT3 receptor antagonist (5-HT3RA) is 
recommended to prevent carboplatin-induced emesis, albeit with moderate level of 
confidence and not unanimous consensus. We performed a meta-analysis of randomized 
trials (RCTs) comparing NK1RA + dexamethasone + 5-HT3RA  vs. dexamethasone + 5-
HT3RA in patients receiving the first cycle of carboplatin-based chemotherapy. Primary 
outcome was complete response (CR), defined as no emesis and no use of rescue 
medication. 9 trials were eligible, and data of CR were available from 8 trials (1598 
patients). Addition of NK1RA improves CR in all phases: acute phase, 94.5% vs. 90.1%; 
delayed phase, 76.4% vs. 61.7%; overall period, 75.3% vs. 60.4%. There was no 
significant heterogeneity among trials. In patients receiving carboplatin-based 
chemotherapy, the addition of NK1RA to dexamethasone and 5-HT3RA is associated with 
a statistically significant and clinically relevant improvement in CR.  
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1. Introduction 
Nausea and vomiting are common adverse events in cancer patients receiving 
chemotherapy [1,2]. Chemotherapy-induced nausea and vomiting (CINV) can significantly 
affect health-related quality of life (QoL) of cancer patients and can impair compliance with 
treatments [3,4]. For these reasons, a correct management of CINV is essential. According 
to guidelines, all antineoplastic agents are classified, based on their emetogenic potential, 
on a 4-group scale: high (emetic risk >90%), moderate (30%–90%), low (10%–30%), and 
minimal (<10%) emetogenic chemotherapy [4]. For each category, guidelines recommend 
different strategies to prevent CINV: a triple drug strategy with 5-hydroxytryptamine type 3 
(5-HT3) receptor antagonists (RAs) plus dexamethasone plus Neurokinin-1 (NK-1) RAs is 
currently recommended in highly emetogenic chemotherapy (HEC) (such as cisplatin-
based treatment or combination of anthracyclines and cyclophosphamide in breast cancer 
patients) to prevent acute and delayed nausea and vomiting [5,6]. In patients receiving 
moderately emetogenic chemotherapy (MEC) such as oxaliplatin and irinotecan, only 5-
HT3RA and dexamethasone are recommended. Instead, for carboplatin, the latest ESMO-
MASCC guidelines recommend a different prophylaxis compared to other MEC, consisting 
in a triple combination of 5-HT3RA plus dexamethasone plus NK-1RA [5]. However, the 
level of confidence was moderate, and the consensus reached among panelists was not 
unanimous. 
To better define the value of NK-1RAs addition in the prevention of emesis for 
patients receiving carboplatin-based chemotherapy, we conducted a systematic review 
and a literature-based meta-analysis of all randomized trials (RCTs) published to date. 
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2. Methods 
This systematic review and meta-analysis was conducted and reported according to 
PRISMA guidelines [7]. Full protocol of the review is available on request from the 
corresponding author. 
The systematic review was performed in January 2017 and updated in June 2017, 
in order to identify all RCTs comparing NK1RA + dexamethasone + 5-HT3RA vs. 
dexamethasone + 5-HT3RA in patients receiving the first cycle of carboplatin-based 
chemotherapy. PubMed search was based on the following key-words: “aprepitant” OR 
“fosaprepitant” OR “netupitant” OR “rolapitant”) AND “carboplatin”. References of the 
selected articles were also checked to identify further eligible trials. Furthermore, the 
proceedings of the main International meetings (American Society of Clinical Oncology, 
European Society of Medical Oncology, Multinational Association of Supportive Care in 
Cancer), were searched from 2010 onwards. 
Both RCTs including only patients receiving carboplatin, and subgroup analyses of 
patients receiving carboplatin within RCTs including various MEC regimens, were 
identified as eligible for the meta-analysis. 
Primary outcome was complete response (CR), defined as no emesis and no use of 
rescue medication. Secondary outcome was the absence of nausea. CR and no nausea 
were measured in day 1 (acute phase), days 2-5 (delayed phase) and days 1-5 (overall 
period).  
Data were extracted independently by two authors (MDM, MM). After data were 
abstracted from each study, meta-analysis was performed using Review Manager 
(RevMan 5.3) software. Given that both complete response and no nausea are  
dichotomous outcomes, cumulative rates were calculated summing up the results obtained 
in each study. For both experimental and control arm, the number of patients obtaining 
complete response and the number of patients obtaining no nausea for each phase (acute, 
5 
 
delayed, overall) was extracted from each article, and input in RevMan as number of 
events (numerator), while the total number of patients assigned to the arm was used as 
denominator.  
Data were pooled using Odds Ratios for complete response and no nausea. A 
random effects model was applied. Statistical heterogeneity between studies was 
examined using the χ2 test and the I2 statistic.   
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3. Results 
Out of 180 records, 173 were excluded and 7 trials were identified as potentially 
eligible (Figure 1) [8-14] . In addition, 2 trials were found in the proceedings of meetings 
[15,16], for a total of 9 trials potentially eligible. More specifically, 7 trials tested the role of 
aprepitant, 1 fosaprepitant and 1 rolapitant; 6 trials were RCTs including only patients 
receiving carboplatin, and 3 were subgroup analyses of patients receiving carboplatin 
within RCTs including various MEC regimens.  
Characteristics of the trials included, in terms of study phase, label (open label vs. 
blinded), randomization procedure, NK1RA used, chemotherapy and antiemetic regimens, 
are detailed in Table 1. One of the trials [8] also included 1 patient who did not receive 
carboplatin-based treatment, but 5-fluorouracil + leucovorin + irinotecan. However, 
considering that all other patients received carboplatin, the trial was considered eligible.  
Data of CR were available in 8 trials [8-15], including 1598 patients: 793 patients 
were assigned to experimental treatment including NK1RA, dexamethasone and 5HT3RA, 
and 805 patients were assigned to control treatment with dexamethasone and 5HT3RA 
alone. Details of CR in each trial arm are reported in Table 2.  
Results of the meta-analysis for primary endpoint (CR) are shown in Figure 2 and 
Figure 3. In the acute phase, the CR rate was significantly higher with addition of NK1RA: 
namely, 94.5% vs 90.1% (Odds Ratio 1.75, 95%CI 1.19-2.59, p=0.005). In the delayed 
phase, the CR rate was significantly higher with addition of NK1RA: 76.4% vs 61.7% 
(Odds Ratio 2.04, 95%CI 1.64-2.55, p<0.00001). Finally, in the overall period (0-120 h), 
the CR rate was significantly higher with the addition of NK1 RA: 75.3% vs 60.4% (Odds 
Ratio 2.04, 95%CI 1.64-2.54, p<0.00001). There was no significant heterogeneity among 
trials, across all the analyses.  
Sensitivity analyses were conducted, excluding open-label trials, and excluding 
subgroup analyses of RCT including various chemotherapy regimens. These sensitivity 
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analyses produced similar results.  More specifically, the sensitivity analysis excluding 
open-label trial was based on 4 trials (1302 patients). The CR rate was significantly higher 
with the addition of NK1RA: namely, 93.8% vs 90.7% (Odds Ratio 1.54, 95%CI 1.01-2.33, 
p=0.04) in the acute phase; 74.9% vs 60.4% (Odds Ratio 2.01, 95%CI 1.58-2.55, 
p<0.00001) in the delayed phase; 73.6% vs 59.4% (Odds Ratio 1.97, 95%CI 1.55-2.50, 
p<0.00001) in the overall period (0-120h), without significant heterogeneity among trials. 
The sensitivity analysis excluding subgroup analyses was based on 6 trials (684 patients). 
The CR rate was significantly higher with the addition of NK1RA: namely, 95.6% vs 89.7% 
(Odds Ratio 2.41, 95%CI 1.23-4.71, p=0.01) in the acute phase; 71.8% vs 57.6% (Odds 
Ratio 1.89, 95%CI 1.36-2.62, p=0.0002) in the delayed phase; 70.6% vs 55.6% (Odds 
Ratio 1.96, 95%CI 1.43-2.71, p<0.0001) in the overall period (0-120h), without significant 
heterogeneity among trials.  
Data of the secondary endpoint (no nausea) were available in 6 trials [8,9,11-14], 
including 1005 patients, for the overall period, and in 5 trials [9,11-14], including 914 
patients, for the acute and delayed phases. Results of the meta-analysis for no nausea are 
shown in Figure 4. In the acute phase, the rate of no nausea was not significantly different 
between treatment groups: namely, 82.7% vs 78.7% (Odds Ratio 1.32, 95%CI 0.75-2.33, 
p=0.33). In the delayed phase, the rate of no nausea was significantly higher with addition 
of NK1RA: 56.0% vs 44.2% (Odds Ratio 1.93, 95%CI 1.14-3.25, p=0.01). Finally, in the 
overall period (0-120 h), the rate of no nausea was significantly higher with the addition of 
NK1 RA: 54.5% vs 42.6% (Odds Ratio 1.77, 95%CI 1.19-2.63, p=0.004). For this endpoint, 
heterogeneity among trials was higher than complete response analysis.  
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4. Discussion 
 In this meta-analysis, we collected the results of all RCTs comparing antiemetic 
prophylaxis based on the combination of 5-HT3RA plus dexamethasone with the same 
combination implemented with a NK1RA, in patients undergoing carboplatin-based 
chemotherapy. Through the comparison of complete response rates (defined as no 
episodes of emesis and no need for rescue medications), we demonstrated that the 
addition of a NK1RA significantly increases the rate of success in the control of CINV after 
the first cycle of chemotherapy. Notably, this benefit was evident in the acute phase 
(absolute difference of about 4%), and was even higher in the delayed phase (absolute 
difference of about 14%, which compares favorably with the benefit obtained from the 
triple combination in highly emetogenic chemotherapy).  
 The combination of dexamethasone and 5-HT3RA has historically been indicated 
as standard antiemetic prophylaxis for patients receiving carboplatin-based regimens [6]. 
However, the efficacy of a two-drug prophylaxis has been reported to be suboptimal, 
especially in the delayed phase [17].  
 The 2016 edition of MASCC/ESMO Consensus Guidelines for the prevention of 
CINV recommends the association of NK1RA, dexamethasone and 5-HT3RA for 
carboplatin-based chemotherapy, even if the level of confidence and consensus among 
panelists was moderate, due to the limitations of clinical studies available [5].  
 The quality and characteristics of trials included in our meta-analysis were 
heterogeneous. However, two sensitivity analyses (performed exclusively on double-blind 
trials and excluding subgroup analyses of RCTs generically including MEC) confirmed the 
main result for the primary endpoint. Furthermore, the meta-analysis did not show 
significant heterogeneity among trials for complete response, neither for the acute nor for 
the delayed phase. 
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 Our meta-analysis supports the use of a three-drug prophylaxis for patients 
undergoing carboplatin-based chemotherapy. As for the acute phase, the absolute CR 
difference in favor of the addition of NK1RA is lower than what is obtained in HEC, and 
below 10%, which is considered by MASCC as a threshold to be clinically meaningful [5]. 
However, given that the proportion of complete responders was already higher than 90% 
in the control arm, the 10% threshold for clinical relevance of this improvement cannot be 
properly applied. As for the delayed and overall phases,  the difference is instead larger 
than the 10% threshold. Most recently, also the NCCN guidelines updated the emetogenic 
status of carboplatin: in the 2.2017 edition, carboplatin-based regimens (when 
administered at area under the curve ≥4 mg/mL per minute) was escalated to HEC, where 
a triple drug regimen should be preferred [18]. Similarly, the recent update of the ASCO 
clinical practice guidelines recommend the addition of a NK1RA for adults who receive 
carboplatin area under the curve ≥4 mg/mL per minute [19]. 
 In the absence of direct comparisons specifically conducted in patients receiving 
carboplatin, no recommendation for a specific NK1RA can be made. Trials available were 
conducted with aprepitant, fosaprepitant and rolapitant, while no trial is available testing 
the addition of netupitant to dexamethasone and 5HT3RA. However, based on a post hoc 
analysis, which indirectly compared netupitant with aprepitant, the recommendation can be 
reasonably extended also to netupitant [20]. Furthermore, although limited by indirectness, 
a randomized trial conducted in patients receiving highly emetogenic chemotherapy 
showed that a triple antiemetic prophylaxis including netupitant was non-inferior compared 
to a triple prophylaxis including aprepitant, with very similar overall CR rates and a similar 
safety profile [21]. However, because no comparative studies are available to assess 
variations in efficacy between different NK1RAs in patients receiving carboplatin, the 
different drug metabolism, the administration route as well as the costs should all be 
elements considered when making a choice.  
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 One limitation of this meta-analysis is the absence of individual patient data. Those 
would have allowed the description of the interaction between treatment efficacy and 
patients characteristics, possibly identifying predictive factors of efficacy. Most of the trials 
including only patients receiving carboplatin [8-13] were conducted in Asian subjects. 
However, several other trials [14-16] were conducted on a global scale and, in our opinion, 
the result can be reasonably applied to all patients independently of ethnicity.  
In addition, one of the eligible trials [16] could not be included in the meta-analysis 
because data on the outcome selected (CR) were not available; nevertheless, the reported 
rate in terms of absence of vomiting confirmed the trend towards an advantage of the 
antiemetic triplet as compared to standard prophylaxis [16].   
 Finally, the endpoint CR defines a success as the absence of emesis and no need 
of rescue drugs, which does not explicitly include nausea. A patient with significant 
nausea, in the absence of rescue medications, would be defined as a success, although 
the impact of nausea on QoL could be relevant. Nausea is challenging, because of its 
subjective nature, and evaluation methods have not evolved in the last decades [22]. 
Among the studies included in our meta-analysis, nausea assessment was variable, with 
two trials using a visual analogue scale (VAS) [11,14], five trials evaluating nausea through 
questionnaires rating the most severe episode that occurred each day [8-10,12,14]. 
Moreover, assessment scales differ among studies, ranging from a two-point (“nausea” 
and “no nausea”) to a five-point scale. For two studies [15,16], no data on nausea were 
available. Bearing in mind these  limitations, we described, as a secondary endpoint, the 
NK1RA efficacy on nausea control, showing a significant improvement with the addition of 
NK1RA, particularly in the delayed phase.. However, because nausea greatly affects 
patients’ QoL, future harmonization of reporting tools in trials evaluating drugs for CINV 
management should be a priority, in order to allow for a more accurate comparison and  
synthesis of the results [23]. Moreover, we believe that the development of a tool 
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assessing longitudinally symptoms such as nausea would add new insights in CINV 
management.  
 In conclusion, the results of our meta-analysis - along with the results of another 
systematic review published in 2017 [24] - underline the benefit of a triple anti-CINV 
premedication incorporating NK1RA for carboplatin-based regimens, as compared to 5-
HT3RA plus dexamethasone prophylaxis. Considering all the available evidence, the entity 
of this benefit is comparable to the benefit obtained with the same combination in cisplatin- 
or antracyclines-based regimens, representing robust evidence to support 
recommendation in clinical practice guidelines.   
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Figure legends 
Figure 1. PRISMA diagram of the study flow for the systematic review and meta-analysis. 
 
Figure 2. Bar graph showing percentage of patients achieving complete response during 
the 120 hours following carboplatin-based chemotherapy administration. Complete 
response was defined as no vomiting and no use of rescue medication. Black bars 
regimen including NK1 receptor antagonist, 5HT3 receptor antagonist and 
dexamethasone, dotted bars regimen including 5HT3 receptor antagonist and 
dexamethasone. Acute phase = 0–24 hours post-chemotherapy, delayed phase = 25–120 
hours post-chemotherapy; overall phase = 0–120 hours post-chemotherapy. 
 
Figure 3. Forest plots of odds ratios (OR) of complete response from randomized trials 
testing the addition of a NK1 receptor antagonist to 5HT3 receptor antagonist plus 
dexamethasone, in patients receiving carboplatin-based chemotherapy. Pooled ORs were 
computed using random-effect models. The bars indicate 95% confidence intervals (CI). 
Panel A: acute phase (0–24 hours post-chemotherapy); Panel B: delayed phase (25–120 
hours post-chemotherapy); Panel C: overall phase (0–120 hours post-chemotherapy). 
 
Figure 4. Forest plots of odds ratios (OR) of no nausea from randomized trials testing the 
addition of a NK1 receptor antagonist to 5HT3 receptor antagonist plus dexamethasone, in 
patients receiving carboplatin-based chemotherapy. Pooled ORs were computed using 
random-effect models. The bars indicate 95% confidence intervals (CI). Panel A: acute 
phase (0–24 hours post-chemotherapy); Panel B: delayed phase (25–120 hours post-
chemotherapy); Panel C: overall phase (0–120 hours post-chemotherapy). 
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Table 1. Characteristics of the eligible trials 
Study Type of study Label Randomization 
procedure 
Chemotherapy Experimental arm Control arm 
Tanioka, 
2013  
[8] 
Randomized 
phase II trial 
Placebo 
 
Computer-
generated, blinded 
allocation schedule 
Carboplatin 
(AUC5 or AUC6) 
plus paclitaxel or 
pemetrexed or 
liposomal 
doxorubicin* 
Day 1: 
Aprepitant 125 mg; granisetron 
1 mg IV; dexamethasone 12 mg 
IV. 
Day 2 and 3: 
Aprepitant 80 mg; 
Dexamethasone 4 mg IV. 
Day 1: 
Granisetron 1 mg IV; 
dexamethasone 20 mg IV. 
Day 2 and 3: 
Dexamethasone 8 mg IV. 
Ito,  
2014 
[9] 
Randomized 
phase II trial 
Open label Central procedure, 
computer-
generated 
Carboplatin AUC 
6 plus paclitaxel 
or pemetrexed 
(+/- bevacizumab) 
Day 1: 
Aprepitant 125 mg; 
1st generation 5-HT3 
antagonist; dexamethasone 8 
mg. 
Day 2 and 3: 
Aprepitant 80 mg; 
dexamethasone 8 mg. 
Day 1: 
1st generation 5-HT3 
antagonist; dexamethasone 8 
mg. 
Day 2 and 3: 
dexamethasone 8 mg. 
Kusagaya, 
2015 
[10] 
Randomized 
phase II trial, 
selection design 
Open label Central procedure, 
computer-
generated 
Carboplatin AUC6 
plus paclitaxel or 
nab-paclitaxel or 
S-1 or 
pemetrexed (+/- 
bevacizumab) 
Day 1: 
Aprepitant 125 mg; 
palonosetron 0.75 mg; 
dexamethasone 8 mg. 
Day 2 and 3: 
aprepitant 80 mg; 
dexamethasone 8 mg. 
Day 1: 
palonosetron 0.75 mg; 
dexamethasone 8 mg. 
Day 2 and 3: 
dexamethasone 8 mg. 
Kaushal,  
2015 
[11] 
Randomized 
trial, no further 
details 
Open label No details Carboplatin 300 
mg/sm + 
docetaxel + 5-
fluorouracil 
Day 1: 
aprepitant 125 mg; 
palonosetron 0.25 mg IV; 
dexamethasone 12 mg IV. 
Day 2 and 3: 
Aprepitant 80 mg; 
Dexamethasone 8 mg orally 
BID. 
Day 1: 
ondansetron 16 mg IV; 
dexamethasone 12 mg IV. 
Day 2 and 3: 
Ondansetron 8 mg orally BID; 
Dexamethasone 8 mg orally 
BID. 
(continues next page) 
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Table 1. Characteristics of the eligible trials (continued) 
Study Type of study Label Randomization 
procedure 
Chemotherapy Experimental arm Control arm 
Maehara,  
2015 
[12] 
Randomized 
trial, no further 
details 
Open label Sealed opaque 
envelopes 
Carboplatin plus 
paclitaxel 
Day 1: 
Aprepitant 125 mg; 
5-HT3 antagonist 3 mg IV; 
dexamethasone 8 or 16 mg IV. 
Day 2 and 3: 
aprepitant 80 mg; 
dexamethasone 4 or 8 mg 
orally. 
Day 1: 
5-HT3 antagonist 3 mg IV; 
dexamethasone 8 or 16 mg IV. 
Day 2 and 3: 
dexamethasone 4 or 8 mg 
orally. 
Yahata, 
2016 
[13] 
Randomized, 
phase II-III trial 
Placebo Central procedure. Carboplatin (AUC 
5 or 6) plus 
paclitaxel 
Day 1: 
aprepitant 125 mg; 
ondansetron 4 mg or granisetron 
1 mg; 
dexamethasone 20 mg IV. 
Day 2 and 3: 
aprepitant 80 mg. 
Day 1: 
ondansetron 4 mg or 
granisetron 1 mg; 
dexamethasone 20 mg IV. 
Day 2 and 3: 
no prophylaxis. 
Hesketh,  
2016 
[14] 
Subgroup 
analysis of a 
randomized 
phase III trial 
Placebo Web-based, central 
procedure. 
Carboplatin alone 
or in combination 
with other 
cytotoxic drugs. 
Day 1: 
rolapitant 180 mg; 
granisetron 2 mg orally; 
dexamethasone 20 mg orally. 
Day 2 and 3: 
granisetron 2 mg orally. 
Day 1: 
granisetron 2 mg orally; 
dexamethasone 20 mg orally. 
Day 2 and 3: 
granisetron 2 mg orally. 
Weinstein,  
2016 
[15] 
Subgroup 
analysis of a 
randomized 
phase III trial 
Placebo Web-based, central 
procedure. 
Carboplatin-
based 
chemotherapy 
Day 1: 
fosaprepitant 150 mg IV; 
ondansetron orally 8 mg + 8 mg 
after 8 hours; 
dexamethasone 12 mg orally. 
Day 2 and 3: 
no prophylaxis. 
Day 1: 
ondansetron 8 mg orally + 8 mg 
after 8 hours; 
dexamethasone 20 mg orally. 
Day 2 and 3: 
ondansetron 8 mg orally BID. 
Gralla,  
2010 
[16] 
Subgroup 
analysis of a 
randomized 
phase III trial 
Placebo Computer-
generated 
procedure. 
Carboplatin-
based 
chemotherapy 
Day 1: 
aprepitant 125 mg; ondansetron 
orally 8 mg + 8 mg after 8 hours; 
dexamethasone 12 mg orally. 
Day 2 and 3: 
aprepitant 80 mg. 
Day 1: 
ondansetron 8 mg orally + 8 mg 
after 8 hours; 
dexamethasone 20 mg orally. 
Day 2 and 3: 
ondansetron 8 mg orally BID. 
*1 patient only did not receive carboplatin-based treatment and received 5-fluorouracil + leucovorin + irinotecan 
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Table 2. Primary endpoint: complete response (no emesis, no use of rescue medication) 
Study Acute phase Delayed phase Overall period 
 Experimental Control Experimental Control Experimental Control 
Tanioka, 2013 
[8] 
44 / 45 
(97.8%) 
44 / 46 
(95.7%) 
28 / 45 
(62.2%) 
24 / 46 
(52.2%) 
28 / 45 
(62.2%) 
24 / 46 
(52.2%) 
Ito, 2014 
[9] 
65 / 66 
(98.5%) 
66 / 67 
(98.5%) 
54 / 66 
(81.8%) 
46 / 67 
(68.7%) 
53 / 66 
(80.3%) 
45 / 67 
(67.2%) 
Kusagaya, 2015 
[10] 
41 / 41 
(100%) 
39 / 39 
(100%) 
33 / 41 
(80.5%) 
30 / 39 
(76.9%) 
33 / 41 
(80.5%) 
30 / 39 
(76.9%) 
Kaushal, 2015 
[11] 
26 / 30 
(86.7%) 
18 / 30 
(60.0%) 
25 / 30 
(83.3%) 
16 / 30 
(53.3%) 
25 / 30 
(83.3%) 
16 / 30 
(53.3%) 
Maehara, 2015 
[12] 
11 / 11 
(100%) 
6 / 12 
(50.0%) 
11 / 11 
(100%) 
8 / 12 
(66.7%) 
11 / 11 
(100%) 
5 / 12 
(41.7%) 
Yahata, 2016 
[13] 
142 / 151 
(94.0%) 
132 / 146 
(90.4%) 
96 / 151 
(63.6%) 
72 / 146 
(49.3%) 
93 / 151 
(61.6%) 
69 / 146 
(47.3%) 
Hesketh, 2016 
[14] 
176 / 192 
(91.7%) 
184 / 209 
(88.0%) 
158 / 192 
(82.3%) 
137 / 209 
(65.6%) 
154 / 192 
(80.2%) 
135 / 209 
(64.6%) 
Weinstein, 2016 
[15] 
243 / 257 
(94.6%) 
236 / 256 
(92.2%) 
201 / 257 
(78.2%) 
164 / 256 
(64.1%) 
200 / 257 
(77.8%) 
162 / 256 
(63.3%) 
Gralla, 2010 
[16] 
n.a. n.a. n.a. n.a. n.a.  n.a. 
OVERALL 
748 / 793 
(94.5%) 
725 / 805 
(90.1%) 
606 / 793 
(76.4%) 
497 / 805 
(61.7%) 
597 / 793 
(75.3%) 
486 / 805 
(60.4%) 
 
